drugset / Trial / NCT05023109
GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC
Phase 2
Unknown
45 enrolled
Shanghai Zhongshan Hospital
Cancer Hospital of Guangxi Medical University · collabJining Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, multi-center, phaseⅡstudy to evaluate the efficacy and safety of GP (Gemcitabine/Cisplatin) in combination with Tislelizumab and Ociperlimab as first-line treatment in participants with unresectable advanced Biliary Tract Carcinoma (BTC).
Timeline
- Start
- 2021-02-01
- Primary completion
- 2023-01-18
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Ociperlimab | Monoclonal antibody | 900 mg | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |